JP2018525994A5 - - Google Patents

Download PDF

Info

Publication number
JP2018525994A5
JP2018525994A5 JP2018510109A JP2018510109A JP2018525994A5 JP 2018525994 A5 JP2018525994 A5 JP 2018525994A5 JP 2018510109 A JP2018510109 A JP 2018510109A JP 2018510109 A JP2018510109 A JP 2018510109A JP 2018525994 A5 JP2018525994 A5 JP 2018525994A5
Authority
JP
Japan
Prior art keywords
cancer
seq
sample
splice variants
leukemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018510109A
Other languages
English (en)
Japanese (ja)
Other versions
JP6876680B2 (ja
JP2018525994A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/049490 external-priority patent/WO2017040526A2/en
Publication of JP2018525994A publication Critical patent/JP2018525994A/ja
Publication of JP2018525994A5 publication Critical patent/JP2018525994A5/ja
Priority to JP2021074145A priority Critical patent/JP7256840B2/ja
Application granted granted Critical
Publication of JP6876680B2 publication Critical patent/JP6876680B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018510109A 2015-09-01 2016-08-30 ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント Active JP6876680B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021074145A JP7256840B2 (ja) 2015-09-01 2021-04-26 ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562212876P 2015-09-01 2015-09-01
US62/212,876 2015-09-01
PCT/US2016/049490 WO2017040526A2 (en) 2015-09-01 2016-08-30 Splice variants associated with neomorphic sf3b1 mutants

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021074145A Division JP7256840B2 (ja) 2015-09-01 2021-04-26 ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント

Publications (3)

Publication Number Publication Date
JP2018525994A JP2018525994A (ja) 2018-09-13
JP2018525994A5 true JP2018525994A5 (enExample) 2019-10-10
JP6876680B2 JP6876680B2 (ja) 2021-05-26

Family

ID=56936518

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018510109A Active JP6876680B2 (ja) 2015-09-01 2016-08-30 ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント
JP2021074145A Active JP7256840B2 (ja) 2015-09-01 2021-04-26 ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021074145A Active JP7256840B2 (ja) 2015-09-01 2021-04-26 ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント

Country Status (5)

Country Link
US (2) US10889866B2 (enExample)
EP (2) EP3344780B1 (enExample)
JP (2) JP6876680B2 (enExample)
ES (1) ES2887201T3 (enExample)
WO (1) WO2017040526A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3344780B1 (en) 2015-09-01 2021-06-23 Eisai R&D Management Co., Ltd. Splice variants associated with neomorphic sf3b1 mutants
JP2020514348A (ja) * 2017-03-15 2020-05-21 エーザイ・アール・アンド・ディー・マネジメント株式会社 スプライセオソーム変異及びその使用
EP3662064A4 (en) * 2017-07-31 2021-07-28 The Johns Hopkins University COMPOSITIONS AND METHODS OF TARGETING MASAS FOR THE TREATMENT OF CANCER WITH SPLEISSOSOME MUTATIONS
CA3096400A1 (en) 2018-04-09 2019-10-17 Eisai R&D Management Co., Ltd. Certain pladienolide compounds and methods of use
IL278740B2 (en) * 2018-06-01 2024-01-01 Eisai R&D Man Co Ltd Methods for using splicing modulators
CN119405833A (zh) 2018-06-01 2025-02-11 卫材R&D管理有限公司 剪接调节抗体-药物缀合物及其使用方法
IL262658A (en) * 2018-10-28 2020-04-30 Memorial Sloan Kettering Cancer Center Prevention of age related clonal hematopoiesis and diseases associated therewith
JP6931860B2 (ja) * 2019-02-08 2021-09-08 株式会社Ｚｅｎｉｃｋ ｍＲＮＡ前駆体の解析方法、情報処理装置、コンピュータプログラム
US20220073971A1 (en) * 2019-02-08 2022-03-10 Zenick Corporation Method for analyzing mrna precursor, information processing apparatus, and computer program
EP3990119A4 (en) * 2019-06-26 2024-03-27 Fred Hutchinson Cancer Center METHODS AND COMPOSITIONS COMPRISING BRD9 ACTIVATION THERAPIES FOR THE TREATMENT OF CANCERS AND RELATED DISORDERS
CN111518805A (zh) * 2020-04-30 2020-08-11 北京航空航天大学 一种可用于抑制肿瘤增殖的非编码基因及其应用
ES2891182A1 (es) * 2020-07-14 2022-01-26 Servicio Andaluz De Salud Compuestos para el tratamiento del carcinoma hepatocelular
CN116507334A (zh) * 2020-11-04 2023-07-28 卫材R&D管理有限公司 骨髓增生异常综合征（mds）的生物标记物及其使用方法
US20240043928A1 (en) 2020-11-04 2024-02-08 Eisai R&D Management Co., Ltd. Biomarkers for myelodysplastic syndrome (mds) and methods of using the same
WO2023131866A1 (en) 2022-01-05 2023-07-13 Eisai R&D Management Co., Ltd. Biomarkers for myelodysplastic syndrome (mds) and methods of using the same
WO2023209074A1 (en) * 2022-04-28 2023-11-02 Institut National de la Santé et de la Recherche Médicale Methods of restoring erythropoiesis in patients suffering from a sf3b1 mutant myelodysplastic syndrome by correcting coasy mis-splicing

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372431B1 (en) * 1999-11-19 2002-04-16 Incyte Genomics, Inc. Mammalian toxicological response markers
DE60119711T2 (de) 2000-02-18 2007-02-22 Centelion Verfahren zur herstellung von funktionalierten polyalkyleniminen, diese enthaltende zusammenstellungen und ihre verwendungen
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
TWI312681B (en) 2001-02-01 2009-08-01 Novel physiologically active substance
US7473767B2 (en) 2001-07-03 2009-01-06 The Institute For Systems Biology Methods for detection and quantification of analytes in complex mixtures
US20070015271A1 (en) * 2002-04-04 2007-01-18 Rosen Craig A Human secreted proteins
TWI334866B (en) 2002-05-29 2010-12-21 Mercian Corp Novel physiologically active substances
US7576204B2 (en) 2002-07-31 2009-08-18 Mercian Corporation Heterocyclic macrolide pharmaceutical agent, a method of producing the same and use of the same
RU2338741C2 (ru) 2002-07-31 2008-11-20 Мершан Корпорейшн Новые физиологически активные вещества
RU2330069C2 (ru) 2002-11-29 2008-07-27 Мершан Корпорейшн Способ получения макролидного соединения и штаммы streptomyces sp., mortierella sp. и micromonosporaceae
CN1886505A (zh) 2003-11-27 2006-12-27 美露香株式会社 参与大环内酯类化合物的羟化作用的dna
CN1977046A (zh) 2004-07-20 2007-06-06 卫材R&D管理有限公司 编码参与普拉地内酯生物合成的多肽的dna
CN101282967B (zh) 2005-10-13 2011-01-26 卫材R&D管理有限公司 普拉二烯内酯b和普拉二烯内酯d的全合成
WO2008111464A1 (ja) * 2007-03-05 2008-09-18 Eisai R & D Management Co., Ltd. スプライシング異常を指標とする抗ガン剤の作用検定方法
US20080312317A1 (en) 2007-04-12 2008-12-18 Eisai R&D Management Co., Ltd. 12 membered-ring macrolactam derivatives
JP5836803B2 (ja) 2008-08-14 2015-12-24 ナノストリング テクノロジーズ， インコーポレイテッド 安定したナノレポーター
WO2011129427A1 (ja) * 2010-04-16 2011-10-20 第一三共株式会社 癌の診断剤および治療剤
MX357402B (es) * 2011-11-08 2018-07-09 Genomic Health Inc Metodo para predecir el pronostico de cancer de mama.
WO2013086464A1 (en) * 2011-12-07 2013-06-13 The Broad Institute, Inc. Markers associated with chronic lymphocytic leukemia prognosis and progression
JP6057408B2 (ja) * 2012-03-05 2017-01-11 国立大学法人 千葉大学 癌の予防剤および／または治療剤
US20140275010A1 (en) 2013-03-12 2014-09-18 Guo Zhu Zheng Quaternary salts
WO2014165753A1 (en) 2013-04-05 2014-10-09 The Wistar Institute Of Anatomy And Biology Methods and compositions for diagnosis of glioblastoma or a subtype thereof
RS58400B1 (sr) 2014-05-15 2019-04-30 Eisai R&D Man Co Ltd Jedinjenja pladienolid piridina i postupci primene
EP3344780B1 (en) 2015-09-01 2021-06-23 Eisai R&D Management Co., Ltd. Splice variants associated with neomorphic sf3b1 mutants

Similar Documents

Publication Publication Date Title
Abbosh et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
Serrano et al. Alterations in the p16INK4a/CDKN2A tumor suppressor gene in gastrinomas
Riveiro-Falkenbach et al. Intra-and inter-tumoral homogeneity of BRAFV600E mutations in melanoma tumors
JP2017512491A5 (enExample)
JP2015210268A5 (enExample)
ES2862331T3 (es) Métodos para predecir el estado de los genes BRCA1 y BRCA2 en una célula de cáncer
JP2019510066A5 (enExample)
Bobba et al. Scar carcinoma of the lung: a historical perspective
Seedor et al. Genetic landscape and emerging therapies in uveal melanoma
Zoghlami et al. BRAF mutation in papillary thyroid carcinoma: predictive value for long-term prognosis and radioiodine sensitivity
RU2018145532A (ru) Композиции и способы диагностирования раковых заболеваний легких с помощью профилей экспрессии генов
ES2947946T3 (es) Métodos para predecir el riesgo de metástasis en melanoma cutáneo
Matsuura et al. CD74-ROS1 fusion transcripts in resected non-small cell lung carcinoma
Chen et al. BRAF mutation may have different prognostic implications in early-and late-stage colorectal cancer
Bohn et al. BRAF V600E mutation and clonal evolution in a patient with relapsed refractory myeloma with plasmablastic differentiation
Kotelevets et al. The Rac1 splice form Rac1b favors mouse colonic mucosa regeneration and contributes to intestinal cancer progression
Dimitrakopoulos et al. Variant of BCL3 gene is strongly associated with five-year survival of non-small-cell lung cancer patients
Xu et al. Circulating Tumor Cells: a window to understand cancer metastasis, monitor and fight against cancers
Jelovac et al. The amplification of c-erb-B2 in cancer-free surgical margins is a predictor of poor outcome in oral squamous cell carcinoma
KR20150132206A (ko) 예측성 바이오마커에 대한 검정법
US20140323344A1 (en) Differential Identification of Pancreatic Cysts
EP4419668A1 (en) Use of nanopore sequencing for determining the origin of circulating dna
Popper et al. The 2020 update of the recommendations of the Austrian working group on lung pathology and oncology for the diagnostic workup of non-small cell lung cancer with focus on predictive biomarkers
Calabria et al. The new challenge in oncology: Next-generation sequencing and its application in precision medicine
Han et al. Homotypic interaction of stabilin-2 plays a critical role in lymph node metastasis of tongue cancer